Lucid Diagnostics

Historical price data

Lucid Diagnostics is a commercial-stage company focused on preventing esophageal adenocarcinoma via early detection of precancerous Barrett's esophagus. Its core achievement is the commercial launch of the EsoGuard/EsoCheck system, a non-endoscopic diagnostic platform with FDA Breakthrough Device designation and established Medicare reimbursement. The company's strategy centers on penetrating the vast, under-screened GERD population through direct sales, strategic partnerships with fire departments, and inclusion in clinical guidelines to drive adoption.

Integrated diagnostic system featuring the EsoCheck swallowable balloon capsule for non-endoscopic esophageal cell collection and the EsoGuard bisulfite-converted NGS assay for detecting DNA methylation biomarkers of Barrett's esophagus and precancer.

Lucid's main competition is the entrenched standard of care (sedated endoscopy) and the Cytosponge/TFF3 test available internationally. Its competitive advantages include first-mover status in the U.S., FDA Breakthrough Device designation, established Medicare reimbursement, and inclusion in major gastroenterology society clinical guidelines.